Skip to main content
. 2023 May 24;14:1200748. doi: 10.3389/fimmu.2023.1200748

Figure 3.

Figure 3

Survival analysis of DLBCL patients after CAR-T therapy (A) OS of total cohort. (B) OS of different HBV subgroup. (C) PFS of total cohort. (D) PFS of different HBV subgroup OS for overall survival; PFS for progression-free survival; CAR-T for chimeric antigen receptor T cell therapy; DLBCL for diffuse large B-cell lymphoma; HBV for hepatitis B virus.